Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

S.W. Lam; S.M. de Groot; A.H. Honkoop; A. Jager; A.J. ten Tije; M.M.E.M. Bos; S.C. Linn; J. van den Bosch; J.R. Kroep; J.J. Braun; H. van Tinteren; E. Boven

doi:10.1016/j.ejca.2014.10.008

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)71502-7 ◽

2011 ◽

Vol 47 ◽

pp. S348

Author(s):

W.J. Gradishar ◽

D.A. Krasnojon ◽

S.V. Cheporov ◽

A.N. Makhson ◽

G.M. Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70439-5 ◽

2014 ◽

Vol 15 (11) ◽

pp. 1269-1278 ◽

Cited By ~ 82

Author(s):

Gunter von Minckwitz ◽

Fabio Puglisi ◽

Javier Cortes ◽

Eduard Vrdoljak ◽

Norbert Marschner ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.610 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 610-610 ◽

Cited By ~ 3

Author(s):

Ahmad Awada ◽

Ramon Colomer ◽

Igor Bondarenko ◽

Kenichi Inoue ◽

Rajendra A. Badwe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70885-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 221 ◽

Cited By ~ 1

Author(s):

I.E. Smith ◽

L. Biganzoli ◽

H. Cortes-Funes ◽

F. Franke ◽

Y. Mostafa Kamel ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety Study ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1140 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1140-1140 ◽

Cited By ~ 1

Author(s):

J. Pierga ◽

K. I. Pritchard ◽

H. Cortes-Funes ◽

L. Biganzoli ◽

C. Thomssen ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Safety Study ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Faculty of 1000 evaluation for Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.717976445.793471388 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-018-05070-2 ◽

2018 ◽

Vol 174 (2) ◽

pp. 433-442 ◽

Cited By ~ 17

Author(s):

O. Nanni ◽

◽

D. Amadori ◽

A. De Censi ◽

A. Rocca ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Clinical Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

OncoTargets and Therapy ◽

10.2147/ott.s103954 ◽

2016 ◽

Vol Volume 9 ◽

pp. 3771-3781 ◽

Cited By ~ 3

Author(s):

Xiao-Qun Liu ◽

Xiangdong Liu ◽

Tiankui Qiao ◽

Wei Chen ◽

Sujuan Yuan

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Randomized Controlled ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Capecitabine-Based Chemoendocrine Combination as First-Line Treatment for Metastatic Hormone-Positive Metastatic Breast Cancer: Phase 2 Study

Clinical Breast Cancer ◽

10.1016/j.clbc.2019.12.012 ◽

2020 ◽

Vol 20 (3) ◽

pp. 228-237 ◽

Cited By ~ 1

Author(s):

Noha Rashad ◽

Thoraya Abdelhamid ◽

Samia A. Shouman ◽

Hanan Nassar ◽

Mervat A. Omran ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

First Line Treatment

Download Full-text

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

BMC Cancer ◽

10.1186/1471-2407-13-164 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 15

Author(s):

Lucia Del Mastro ◽

Alessandra Fabi ◽

Mauro Mansutti ◽

Michele De Laurentiis ◽

Antonio Durando ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Trial ◽

First Line Treatment

Download Full-text